On May 3, 2018, Merck and Moderna Therapeutics, a biotechnology company focused on messenger RNA (mRNA) drug discovery and drug development, announced an expansion of their 2016 partnership to develop and commercialize novel personalized messenger mRNA cancer vaccines to include shared-antigen mOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.